Ennis Ford Perfect Drive
Ennis Daily News

Infant liquid ibuprofen sold at Walmart, CVS and Family Dollar recalled


Several brands of infant liquid ibuprofen are being recalled as they might contain higher, and potentially more dangerous, concentrations of the drug. New Jersey-based Tris Pharma Inc. is recalling the “Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL” product sold and packaged in 0.5 oz. bottles at CVS Pharmacy, Family Dollar and Walmart, according to a news release. Brand names include CVS Health, Family Wellness and Equate, respectively. Side effects of higher concentrations of ibuprofen include nausea, vomiting, gastrointestinal bleeding and other issues. Infants more susceptible to a higher potency could be more at risk of NSAID-associated renal injury, the company says. Walmart lot numbers include 00717009A (02/19 expiration), 00717015A (04/19 expiration) and 00717024A (08/19 expiration). CVS lot is 00717024A (08/19 expiration) and Family Dollar lot is 00717024A (08/19 expiration). Tris Pharma has not received any reports of illness with its products, it says. © 2018 WTSP

Post to Twitter

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Comments

comments

Posted by on Dec 7 2018. Filed under National news. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

You must be logged in to post a comment Login

Featured Links

    Search Archive

    Search by Date
    Search by Category
    Search with Google

    Photo Gallery

    Log in

     

    Copyright: All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Ennis Daily News content, including by framing or similar means, is expressly prohibited without the prior written consent of Ennis Daily News. Ennis Daily News and its logo are registered trademarks or trademarks of the Ellis County Newspapers, Inc.

    © Ellis County Newspapers, Inc. 2018